Protalix BioTherapeutics
PLX
36 hedge funds and large institutions have $4.63M invested in Protalix BioTherapeutics in 2017 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 11 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
6% more funds holding
Funds holding: 34 → 36 (+2)
0.32% less ownership
Funds ownership: 0.83% → 0.5% (-0.32%)
27% less capital invested
Capital invested by funds: $6.39M → $4.63M (-$1.75M)
45% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$1.23M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$76.8K |
| 3 |
CIBC Private Wealth Group
Atlanta,
Georgia
|
+$16.9K |
| 4 |
Bank of New York Mellon
New York
|
+$7.84K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$6.41K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
-$2.77M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$1.16M |
| 3 |
Renaissance Technologies
New York
|
-$72.7K |
| 4 |
BlackRock
New York
|
-$55K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$25K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WS
26
Wedbush Securities
Los Angeles,
California
| $10K | -$5.4K | -800 | -35% |
|
27
Citigroup
New York
| $9K | – | – | – |
|
|
28
Bank of New York Mellon
New York
| $8K | +$7.84K | +1,162 | New |
|
29
Simplex Trading
Chicago,
Illinois
| $7K | -$4.52K | -670 | -38% |
|
|
CB
30
Commerce Bank
Kansas City,
Missouri
| $7K | – | – | – |
|
31
Bank of America
Charlotte,
North Carolina
| $7K | +$2.09K | +310 | +37% |
|
32
Royal Bank of Canada
Toronto,
Ontario, Canada
| $3K | – | – | – |
|
33
SEI Investments
Oaks,
Pennsylvania
| $2K | – | – | – |
|
|
FDCDDQ
34
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $1.65K | – | – | – |
|
|
ASN
35
Advisory Services Network
Atlanta,
Georgia
| $1K | – | – | – |
|
36
Parallax Volatility Advisers
San Francisco,
California
| $1K | – | – | – |
|
|
37
BlackRock
New York
| – | -$55K | -9,420 | Closed |
|
|
OAM
38
Oxford Asset Management
Oxford,
United Kingdom
| – | -$25K | -4,214 | Closed |
|
|
HIIFS
39
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
| – | -$12K | -2,000 | Closed |
|
PLX Hedge Fund Activity: Q4 2017 in Review
36 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q4 2017, worth a combined $4.63M — down 27% from $6.39M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new PLX positions and 3 closed out — a net gain of 2 holders — while 6 added to existing stakes and 11 trimmed.
The largest buyer was Opaleye Management, opening a new position worth an estimated $1.23M. The largest seller was Highbridge Capital Management, cutting an estimated $2.77M.
- 36 institutional investors held Protalix BioTherapeutics (PLX) as of Q4 2017, up from 34 in Q3 2017.
- Funds reported $4.63M of Protalix BioTherapeutics stock for Q4 2017, down 27% quarter-over-quarter.
- 5 funds opened new Protalix BioTherapeutics positions in Q4 2017 and 3 closed out, a net change of +2 holders.
- The largest Protalix BioTherapeutics buyer in Q4 2017 was Opaleye Management, an estimated $1.23M added.
- The largest Protalix BioTherapeutics seller in Q4 2017 was Highbridge Capital Management, an estimated $2.77M sold.
Based on aggregated 13F filings for Q4 2017.